



Exonbio launches high affinity SARS-CoV-2 rabbit monoclonal antibodies to accelerate the global IVD and research community efforts

SAN DIEGO, Calif., July 23, 2020 /PRNewswire/ -- Exonbio, a leading recombinant antibody development service provider company now launches the SARS-CoV-2 Nucleocapsid recombinant monoclonal antibodies for the global IVD and research communities in support of efforts to combat the pandemic. Since the emergence of COVID-19 outbreak, Exonbio has developed a comprehensive portfolio of SARS-CoV-2 recombinant rabbit antibodies using its proprietary [Single Plasma Cell Interrogation \(SPIN®\) platform](#).

Exonbio has screened hundreds of clones of rabbit monoclonal antibodies by surface plasmon resonance (SPR) with Biocore 3000 and identified high affinity clones to recombinant full-length [nucleocapsid protein of SARS CoV-2](#). There are 12 clones with an EC50 of less than 1 ng/ml, with the most potent clone being 6F2 at EC50 of 0.37 ng/ml (2.5pM). Epitope mapping suggested at least 5 well separated epitopes, so there are multiple choices for selecting the pairs for sandwich ELISA and other applications which requires a pair of antibodies.

The SARS-CoV-2 nucleocapsid (N) protein is highly homologous to the N protein of SARS-CoV, which is essential for viral RNA replication and packaging into new virions. By using Exonbio's SPIN® technology platform, highly specific antibodies from plasma cells are generated against nucleocapsid protein of SARS-CoV-2. The recombinant nucleocapsid antibodies developed has no cross reactivity to human coronavirus nucleocapsid protein.

The recombinant nucleocapsid antibody is highly specific to the mammalian-expressed nucleocapsid protein of the SARS CoV-2. These antibodies can be used with various applications like ELISA, Lateral Flow assay, immunohistochemistry (IHC), Flow cytometry.

"Exonbio antigens and antibodies are a critical tool to the life science community to accelerate the research to understand COVID-19. The high affinity anti-NP antibody provides a critical reagent for the development of rapid antigen diagnostic kit against this virus," said Dr. Kunhua Chen, Exonbio's Chief Executive Officer.

To learn more about the SARS-CoV-2 antibodies, visit: www.exonbio.com or contact our team: antibody@exonbio.com.

About Exonbio:

Exonbio is a leading recombinant protein and antibody developer. Exonbio's novel proprietary Single Plasma cell INterrogation (SPIN®) technology is capable of developing monoclonal antibodies with broad epitope coverage and high affinity. Thus, has made the technology perfect for therapeutic and diagnostic antibody development.

Contact Name: Kunhua Chen
Phone: 858-457-1920
Email: kchen@exonbio.com
Website: www.exonbio.com

